Systemic immune‐inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non‐small cell lung cancer

Abstract

The SII is a promising prognostic predictor for patients with surgically resected NSCLC and retained prognostic significance in the lung adenocarcinoma subgroup. The prognostic value of the SII is superior to the NLR and PLR.